| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | cimetidine | CTRPv2 | pan-cancer | AAC | 0.071 | 0.3 |
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | -0.048 | 0.3 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | 0.051 | 0.3 |
| mRNA | Nutlin-3 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.3 |
| mRNA | BRD-K99584050 | CTRPv2 | pan-cancer | AAC | -0.053 | 0.3 |
| mRNA | MLN2238 | CTRPv2 | pan-cancer | AAC | 0.034 | 0.3 |